Joshua Posner
Pharmacist
3500 Gaston Ave, Dallas
Texas, 75246-2017
214-820-0111 Joshua Posner is a pharmacist in Dallas, Texas. Patients can reach him at 3500 Gaston Ave, Dallas or contact him on 214-820-0111. Active license number of Joshua Posner is 74206 for Pharmacist in Texas.
Joshua Posner is
Complete Profile:
Joshua Posner speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
| Name: | Joshua Posner |
| Specialization: | Pharmacist |
| Credentials: | PHARMD |
| Gender: | Male |
| Location: | 3500 Gaston Ave, Dallas,
Texas, 75246-2017 |
| Phone: | 214-820-0111 |
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Joshua Posner are as mentioned below.
| NPI Number: | 1881426849 |
| NPI Enumeration Date: | 19 Aug, 2024 |
| NPI Last Update On: | 19 Aug, 2024 |
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Joshua Posner are as mentioned below.
| Specialization | License Number | State | Status | |
| Pharmacist | 74206 | Texas | Primary | |
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
| Address: | 2901 Indiana Blvd Apt 336,
Dallas, Texas |
| Zip: | 75226-1546 |
| Phone Number: | 240-388-7139 |
Patients can reach Joshua Posner at
3500 Gaston Ave, Dallas, Texas or can
call on phone at 214-820-0111.
Comments/ Reviews:
Read all the reviews posted for Joshua Posner below. You may also share your own experience with Joshua Posner. Your feedback can help others make better decisions.
**Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 08 December, 2025.